window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 20, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Drug Delivery

  • Central Nervous System,Clinical Development,Drug Delivery & Formulation,Drug Development,Neurosciences,Patient Centricity

    Emalex secures US patent for ecopipam orally disintegrating tablet in Tourette syndrome

    Emalex Biosciences has secured a US patent for an orally [...]

    April 11, 2026
  • Biotech,Drug Delivery & Formulation,Drug Development,Partnerships & Funding,Pharmaceuticals and therapeutics

    Bio-Sourcing and Tiny Cargo partner to develop oral monoclonal antibodies using milk exosomes

    Bio-Sourcing and Tiny Cargo will develop oral monoclonal antibody therapies [...]

    March 30, 2026
  • Clinical Development,Clinical studies,Drug Delivery & Formulation,European biotech,Obesity,Research & Development

    Nanexa targets next-generation ‘fat jab’ with monthly semaglutide delivery platform

    Sweden-based Nanexa has reported preclinical data for a long-acting semaglutide [...]

    January 29, 2026
  • Biologics & Biosimilars,Biotech,Drug Development,Oncology,Pharmaceuticals and therapeutics,Technology and platforms

    Bio‑Sourcing and Zerion Pharma collaborate on first oral HER2 monoclonal antibody

    Bio‑Sourcing and Zerion Pharma have joined forces to develop the [...]

    January 12, 2026
  • Drug Delivery & Formulation,Events and Conferences,Manufacturing,Packaging,Sustainability

    Pharmapack 2026 to return to Paris with focus on GLP-1 therapies and sustainable packaging

    Pharmapack will return to Paris in January 2026, with this [...]

    January 8, 2026
  • Drug Delivery & Formulation,Pharmaceuticals and therapeutics,Research & Development,Technology and platforms

    Nanexa and Moderna sign licence and option agreement for Pharmashell drug delivery development

    Nanexa has entered into a licence and option agreement with [...]

    December 12, 2025
  • Biotech,Clinical Development,Drug Development,European biotech,Events and Conferences,Partnerships & Funding,Pharmaceuticals and therapeutics,Women in Pharma

    CPHI Frankfurt Pharma Awards 2025 finalists unveiled, spotlighting innovation, sustainability and industry leadership

    From synthetic biology to patient access, AI-powered formulation to sustainable [...]

    September 26, 2025
  • Drug Delivery & Formulation,Pharmaceuticals and therapeutics,Technology and platforms

    Nanexa secures Japanese patent for PharmaShell technology

    Nanexa has received approval for a Japanese patent covering a [...]

    September 23, 2025
  • CDMOs & Manufacturing,Drug Delivery & Formulation,Pharmaceuticals and therapeutics

    SGD Pharma to acquire Alphial to expand tubular glass and vial manufacturing in Europe

    SGD Pharma has signed an agreement with Italian private equity [...]

    September 7, 2025
  • CDMOs & Manufacturing,Cell & Gene Therapy,Drug Delivery & Formulation,Partnerships & Funding,Technology and platforms

    LNP pioneer Pieter Cullis joins Hongene’s scientific advisory board

    Hongene has appointed leading lipid nanoparticle (LNP) researcher Pieter Cullis [...]

    August 5, 2025
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Click Therapeutics secures $50M from Boehringer Ingelheim for schizophrenia digital therapy
    Categories: Clinical Development, Clinical Trials, Digital Health, Funding, Mental health, Neurosciences, Pharmaceuticals and therapeutics
  • Kainova Therapeutics doses first patient in Europe in phase 1/2 anti-CCR8 antibody trial
    Categories: Clinical Trials, Oncology
  • START appoints Salwan Al Mutar to lead clinical research in Dallas-Fort Worth
    Categories: Clinical Development, Clinical Trials, Healthcare leadership, Oncology
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top